ijms-logo

Journal Browser

Journal Browser

Neuroblastoma Molecular Biology and Therapeutics 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 August 2022) | Viewed by 2424

Special Issue Editor


E-Mail Website
Guest Editor
1. Departamento de Biología Celular, Facultad de Biología, Universidad de Sevilla, 41012 Seville, Spain
2. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, 41013 Seville, Spain
Interests: cancer; metastasis; adhesion; cell migration; Rho GTPases; neuroblastoma; cellular signalling

Special Issue Information

Dear Colleagues,

As for most childhood cancers, the search of new treatments for neuroblastoma has been largely neglected by the pharmaceutical industry, even though preventive measures are not possible for the affected population. Despite improvements in the last decades, high-risk neuroblastoma is still responsible for most of the deaths of cancer patients below one year of age, and resistant aggressive relapses after treatment are still a major challenge in neuroblastoma progression. Recent collaborative efforts have put together a large collection of neuroblastoma tumor samples and developed a new deep genetic characterization to help prognosis and treatment. However, the complex biology of the disease at the cellular and molecular level is still not well understood. Known genetic drivers of the disease are scarce, and a combination of genetic, epigenetic, and developmental factors might be involved in neuroblastoma initiation and progression. Intratumor cellular heterogeneity has also emerged as an important feature in aggressive neuroblastoma progression, with the involvement of different tumor cell populations at different differentiation stages, together with stromal components. A deeper understanding of the signaling pathways and cellular interactions acting within a tumor would provide new druggable targets and therapeutic strategies to stop neuroblastoma progression and overcome resistance to the current therapies.

In this context, I would like to invite review and original articles that address the latest findings in the cellular and molecular characterization of neuroblastoma, including new therapeutic venues and molecules.

Dr. Francisco M. Vega
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuroblastoma biology
  • cellular heterogeneity
  • cellular plasticity
  • signaling
  • molecular targets
  • differentiation
  • tumor microenvironment
  • drug discovery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

23 pages, 9682 KiB  
Article
Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells
by Lucia Cappabianca, Michela Sebastiano, Marianna Ruggieri, Maddalena Sbaffone, Veronica Zelli, Antonietta Rosella Farina and Andrew Reay Mackay
Int. J. Mol. Sci. 2022, 23(18), 10895; https://doi.org/10.3390/ijms231810895 - 17 Sep 2022
Cited by 3 | Viewed by 2158
Abstract
Patients with advanced neuroblastoma (NB) receive multimodal clinical therapy, including the potent anthracycline chemotherapy drug doxorubicin (Dox). The acquisition of Dox resistance, however, is a major barrier to a sustained response and leads to a poor prognosis in advanced disease states, reinforcing the [...] Read more.
Patients with advanced neuroblastoma (NB) receive multimodal clinical therapy, including the potent anthracycline chemotherapy drug doxorubicin (Dox). The acquisition of Dox resistance, however, is a major barrier to a sustained response and leads to a poor prognosis in advanced disease states, reinforcing the need to identify and inhibit Dox resistance mechanisms. In this context, we report on the identification and inhibition of a novel Dox resistance mechanism. This mechanism is characterized by the Dox-induced activation of the oncogenic TrkAIII alternative splice variant, resulting in increased Dox resistance, and is blocked by lestaurtinib, entrectinib, and crizotinib tyrosine kinase and LY294002 IP3-K inhibitors. Using time lapse live cell imaging, conventional and co-immunoprecipitation Western blots, RT-PCR, and inhibitor studies, we report that the Dox-induced TrkAIII activation correlates with proliferation inhibition and is CDK1- and Ca2+-uniporter-independent. It is mediated by ryanodine receptors; involves Ca2+-dependent interactions between TrkAIII, calmodulin and Hsp90; requires oxygen and oxidation; occurs within assembled ERGICs; and does not occur with fully spliced TrkA. The inhibitory effects of lestaurtinib, entrectinib, crizotinib, and LY294002 on the Dox-induced TrkAIII and Akt phosphorylation and resistance confirm roles for TrkAIII and IP3-K consistent with Dox-induced, TrkAIII-mediated pro-survival IP3K/Akt signaling. This mechanism has the potential to select resistant dormant TrkAIII-expressing NB cells, supporting the use of Trk inhibitors during Dox therapy in TrkAIII-expressing NBs. Full article
(This article belongs to the Special Issue Neuroblastoma Molecular Biology and Therapeutics 2.0)
Show Figures

Figure 1

Back to TopTop